Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2788657 | 0.88 | KEAP1 (0.59) | KEAP1NFE2L2KIF11CHRM3CHRM2 | |
| SCHEMBL27351967 | 0.85 | KEAP1 (0.51) | KEAP1NFE2L2KIF11CHRM3CHRM2 | |
| SCHEMBL8860365 | 0.82 | KEAP1 (0.56) | KEAP1NFE2L2KIF11CHRM3CHRM2 | |
| SCHEMBL3761188 | 0.78 | CYP1A2 (0.47) | KEAP1NFE2L2KIF11CHRM3CHRM2 | |
| SCHEMBL6577781 | 0.77 | KEAP1 (0.62) | KEAP1NFE2L2KIF11CHRM3CHRM2 | |
| SCHEMBL2656123 | 0.76 | CHRM3 (0.55) | KEAP1NFE2L2KIF11CHRM3CHRM2 | |
| SCHEMBL29116795 | 0.75 | KEAP1 (0.56) | KEAP1NFE2L2KIF11CHRM3CHRM2 | |
| SCHEMBL9940816 | 0.74 | KEAP1 (0.55) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL17739911 | 0.74 | KEAP1 (0.54) | KEAP1NFE2L2KIF11CHRM3CHRM2 | |
| SCHEMBL31025938 | 0.74 | KEAP1 (0.48) | KEAP1NFE2L2KIF11CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488748-B2 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-10 | — | — | US | disclosed |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-02 | — | — | US | disclosed |
| EP-1590325-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067510-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-12 | — | — | WO | disclosed |
| US-5192779-A | Substituted-acetamide compound and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-09 | — | — | US | disclosed |
| US-5066680-A | NOVEL SUBSTITUTED-ACETAMIDE COMPOUND AND A PROCESS FOR THE PREPARATION THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-19 | — | — | US | disclosed |
| CN-1044938-A | Acetamide compound of a kind of new replacement and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1990-08-29 | — | — | CN | disclosed |
| EP-0383256-A2 | A novel substituted-acetamide compound and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | KEAP1 1389/4885NFE2L2 3502/4885KIF11 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.